Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by Enanta Pharmaceuticals, Inc. on February 28, 2018. The company is incorporated in Delaware and is headquartered in Watertown, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal No. 1: Election of Class II Directors
- George S. Golumbeski, Ph.D.: Re-elected with 7,906,803 votes for and 6,293,582 votes withheld.
- Kristine Peterson: Re-elected with 13,793,479 votes for and 406,906 votes withheld.
- Terry C. Vance: Re-elected with 14,146,357 votes for and 54,028 votes withheld.
- Broker Non-Votes: 1,522,744 shares were recorded as broker non-votes for all director nominees.
- Proposal No. 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2018.
- Votes For: 15,697,073
- Votes Against: 23,181
- Abstain: 2,875
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- George S. Golumbeski received a significant number of withheld votes (6,293,582) compared to the other nominees, though he was still re-elected.
- The ratification of PricewaterhouseCoopers LLP passed with overwhelming support (over 15.6 million votes for vs. 23,181 against).
- There were 1,522,744 broker non-votes regarding the director elections, which may indicate brokers did not have discretionary authority to vote on these matters.
- The definitive proxy statement filed on January 19, 2018, contains detailed descriptions of the proposals.